Serephine的个人主页 - 老虎社区

Serephine

Serephine

暂无个人介绍

IP属地：未知

20关注

3粉丝

0主题

0勋章

2021-11-30

Oh wells

5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market

2021-11-18

$AMC Entertainment(AMC)$Up up and away 🎈🎈🎈

2021-11-30

[开心]

4 Stocks Billionaires Are Buying Hand Over Fist

2021-11-30

That's great

These 3 Charts Should Have Nio Investors Excited

2021-11-20

$NIO Inc.(NIO)$BBelieve in it

2021-11-18

$Sono Group N.V.(SEV)$ttought that wouldn't make it [得意]

2021-11-30

Oh

Gaming stocks jumped in morning trading

2021-11-29

Oo

5 Stocks To Watch For November 29, 2021

2021-11-24

Oo

5 Stocks To Watch For November 24, 2021

2021-11-20

Not earning much as compared to prev record but all good

2021-11-19

$Sono Group N.V.(SEV)$😅

2021-11-18

This is nice ☺️

2021-11-17

[财迷]

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":4099890130933260,"uuid":"4099890130933260","gmtCreate":1636787880960,"gmtModify":1636986423119,"name":"Serephine","pinyin":"serephine","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":20,"tweetSize":13,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.19","exceedPercentage":"60.89%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":609268524,"gmtCreate":1638286630401,"gmtModify":1638286630499,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[开心]&nbsp;","listText":"[开心]&nbsp;","text":"[开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609268524","repostId":"2187817235","repostType":4,"repost":{"id":"2187817235","pubTimestamp":1638279553,"share":"https://www.laohu8.com/m/news/2187817235?lang=&edition=full","pubTime":"2021-11-30 21:39","market":"us","language":"en","title":"4 Stocks Billionaires Are Buying Hand Over Fist","url":"https://stock-news.laohu8.com/highlight/detail?id=2187817235","media":"Motley Fool","summary":"Successful money managers purchased a number of unexpected stocks in the third quarter.","content":"<p>You may not realize it, but one of the most important data releases of the quarter occurred approximately two weeks ago.</p>\n<p>On Nov. 15, institutional investors and hedge funds with at least $100 million in assets under management were required to file Form 13F with the Securities and Exchange Commission (SEC). A 13F provides Wall Street and investors with an under-the-hood look at what the smartest money managers were buying and selling in the previous quarter (i.e., the third quarter). Though 13Fs are a bit dated by the time they're filed with the SEC (holdings are as of Sept. 30, 2021), they still provide valuable clues of what's catching the attention of the world's most successful fund managers.</p>\n<p>With the latest round of 13Fs, one thing stands out: billionaires were buying stocks hand over fist. However, they didn't necessarily buy the names you'd expect.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F654909%2Fbusinessman-looking-at-ticker-board-stock-market-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Ken Griffin (Citadel Advisors): Tesla Motors</h2>\n<p>Billionaire Ken Griffin is a wildly successful investor who's known for extracting big wins from his firms' options positions. But the big story from the third quarter is that Citadel made electric vehicle (EV) manufacturer <b>Tesla Motors</b> (NASDAQ:TSLA) its largest non-options holding. Griffin's fund bought close to 1.8 million shares of Tesla in the third quarter, increasing its position by 873% from the end of June.</p>\n<p>Why Tesla? One logical explanation is that EVs are inevitable. Pretty much every major economic powerhouse worldwide is focused on reducing carbon emissions going forward. Perhaps the easiest way to make a dent in carbon emissions is to push a multi-decade vehicle replacement cycle.</p>\n<p>A more likely explanation for Griffin's interest in Tesla is the company's first-mover advantage. Even with an ongoing semiconductor chip shortage, Tesla looks to be on pace to hit 800,000 (or more) EV deliveries in 2021. Further, it could reasonably pace 50% annual delivery growth over the next couple of years as new gigafactories come online. With no other automakers coming close (at the moment) to its combination of battery range, power, and capacity, Griffin likely feels he and his fund can ride this momentum higher.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F654909%2Fko-drink-bottle.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"><span>Image source: Coca-Cola.</span></p>\n<h2>Jim Simons (Renaissance Technologies): Coca-Cola</h2>\n<p>For a highly diversified fund known for its love of innovation, the shock of the quarter might just be that billionaire Jim Simons was buying beverage giant <b>Coca-Cola</b> (NYSE:KO) hand over fist. All told, Renaissance Technologies added a little over 6 million shares of Coke in the third quarter, which more than tripled its stake as of the end of June.</p>\n<p>With the benchmark <b>S&amp;P 500</b> taking less than 17 months to double from its coronavirus bear-market bottom, Simons' substantially increased stake in Coke might be a means of playing it safe and hedging his funds' bets. Since Coca-Cola has a presence in all but two countries worldwide (Cuba and North Korea), and its portfolio sports more than 20 brands generating at least $1 billion in annual sales, it's a safe bet to generate modest returns -- or at worst hold up much better than the broader market if a crash or correction strikes.</p>\n<p>Coca-Cola is also a relatively smart inflation play. The company is parsing out a hearty 3.1% yield, has raised its base annual dividend for 59 consecutive years, and its well-known brand makes it easy for the company to pass along higher costs to its customers.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F654909%2Fmature-woman-shopping-mall-retail-gdp-clothing-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>David Tepper (Appaloosa): Macy's</h2>\n<p>In a market dominated by growth stocks, billionaire David Tepper headed to the retail counter in the third quarter and piled into department store <b>Macy's</b> (NYSE:M). Tepper's Appaloosa purchased 3.39 million shares, which lifted the fund's stake to an even 7 million shares.</p>\n<p>Scratching your head as to why a successful money manager is buying into an old-school retailer? The answer looks to be Macy's, thus far, solid execution on its three-year Polaris strategy. In no particular order, this strategy includes:</p>\n<ul>\n <li>Closing underperforming stores and reducing corporate and store-level staff to cut expenses.</li>\n <li>Emphasizing digital sales channels, which are a high-growth opportunity for the company until the pandemic ends (and perhaps well after).</li>\n <li>Increasing customer engagement through its loyalty rewards program.</li>\n <li>Focusing its efforts of a small number of higher-margin private brands.</li>\n</ul>\n<p>Although Macy's has challenges to overcome, such as continuing to pay down more than $6 billion in debt, the initial results show its digitization and branding efforts are paying off. The company ended September with 4.4 million new customers, up 28% from the comparable period in 2019 (i.e., before the pandemic). Additionally, 33% of net sales derived online, up from 23% in Q3 2019.&nbsp; If these arrows continue to point higher, Tepper may have found himself a bargain.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F654909%2Fwoman-talk-smartphone-city-wireless-5g-4g-data-voicemail-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Israel Englander (Millennium Management): AT&amp;T</h2>\n<p>Like Ken Griffin, billionaire Israel Englander is a big fan of utilizing put and call options to maximize returns for his fund, Millennium Management. However, the big buy in the third quarter was stodgy telecom giant <b>AT&amp;T</b> (NYSE:T). Englander's fund bought up close to 11.2 million shares, which increased its stake by 165% from the sequential second quarter.</p>\n<p>Similar to Coca-Cola, buying AT&amp;T is a play on value and stability in a very pricey market. For the time being, it's paying out an inflation-topping 8.6% yield and can be purchased for a little north of 7 times Wall Street's estimated earnings per share this year.</p>\n<p>But what might have wet Englander's whistle is AT&amp;T's plan to spin off its content arm, WarnerMedia, and combine it with <b>Discovery</b>. Combining forces will save more than $3 billion in annual costs and vastly improve original and sports programming options for streaming customers. Most importantly, it'll allow AT&amp;T to reduce its debt (and its dividend, as well) and focus on growing its wireless business with the ongoing rollout of 5G infrastructure.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Stocks Billionaires Are Buying Hand Over Fist</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Stocks Billionaires Are Buying Hand Over Fist\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 21:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/30/4-stocks-billionaires-are-buying-hand-over-fist/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may not realize it, but one of the most important data releases of the quarter occurred approximately two weeks ago.\nOn Nov. 15, institutional investors and hedge funds with at least $100 million ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/30/4-stocks-billionaires-are-buying-hand-over-fist/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4515":"5G概念","BK4532":"文艺复兴科技持仓","BK4177":"软饮料","M":"梅西百货","BK4534":"瑞士信贷持仓","BK4507":"流媒体概念","BK4555":"新能源车","EV":"MAST GLOBAL BATTERY RECYCLING & PRODUCTION ETF","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","KO":"可口可乐","BK4115":"综合电信业务","TSLA":"特斯拉","BK4551":"寇图资本持仓","BK4103":"百货商店","BK4504":"桥水持仓","T":"美国电话电报","BK4099":"汽车制造商","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/11/30/4-stocks-billionaires-are-buying-hand-over-fist/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2187817235","content_text":"You may not realize it, but one of the most important data releases of the quarter occurred approximately two weeks ago.\nOn Nov. 15, institutional investors and hedge funds with at least $100 million in assets under management were required to file Form 13F with the Securities and Exchange Commission (SEC). A 13F provides Wall Street and investors with an under-the-hood look at what the smartest money managers were buying and selling in the previous quarter (i.e., the third quarter). Though 13Fs are a bit dated by the time they're filed with the SEC (holdings are as of Sept. 30, 2021), they still provide valuable clues of what's catching the attention of the world's most successful fund managers.\nWith the latest round of 13Fs, one thing stands out: billionaires were buying stocks hand over fist. However, they didn't necessarily buy the names you'd expect.\nImage source: Getty Images.\nKen Griffin (Citadel Advisors): Tesla Motors\nBillionaire Ken Griffin is a wildly successful investor who's known for extracting big wins from his firms' options positions. But the big story from the third quarter is that Citadel made electric vehicle (EV) manufacturer Tesla Motors (NASDAQ:TSLA) its largest non-options holding. Griffin's fund bought close to 1.8 million shares of Tesla in the third quarter, increasing its position by 873% from the end of June.\nWhy Tesla? One logical explanation is that EVs are inevitable. Pretty much every major economic powerhouse worldwide is focused on reducing carbon emissions going forward. Perhaps the easiest way to make a dent in carbon emissions is to push a multi-decade vehicle replacement cycle.\nA more likely explanation for Griffin's interest in Tesla is the company's first-mover advantage. Even with an ongoing semiconductor chip shortage, Tesla looks to be on pace to hit 800,000 (or more) EV deliveries in 2021. Further, it could reasonably pace 50% annual delivery growth over the next couple of years as new gigafactories come online. With no other automakers coming close (at the moment) to its combination of battery range, power, and capacity, Griffin likely feels he and his fund can ride this momentum higher.\nImage source: Coca-Cola.\nJim Simons (Renaissance Technologies): Coca-Cola\nFor a highly diversified fund known for its love of innovation, the shock of the quarter might just be that billionaire Jim Simons was buying beverage giant Coca-Cola (NYSE:KO) hand over fist. All told, Renaissance Technologies added a little over 6 million shares of Coke in the third quarter, which more than tripled its stake as of the end of June.\nWith the benchmark S&P 500 taking less than 17 months to double from its coronavirus bear-market bottom, Simons' substantially increased stake in Coke might be a means of playing it safe and hedging his funds' bets. Since Coca-Cola has a presence in all but two countries worldwide (Cuba and North Korea), and its portfolio sports more than 20 brands generating at least $1 billion in annual sales, it's a safe bet to generate modest returns -- or at worst hold up much better than the broader market if a crash or correction strikes.\nCoca-Cola is also a relatively smart inflation play. The company is parsing out a hearty 3.1% yield, has raised its base annual dividend for 59 consecutive years, and its well-known brand makes it easy for the company to pass along higher costs to its customers.\nImage source: Getty Images.\nDavid Tepper (Appaloosa): Macy's\nIn a market dominated by growth stocks, billionaire David Tepper headed to the retail counter in the third quarter and piled into department store Macy's (NYSE:M). Tepper's Appaloosa purchased 3.39 million shares, which lifted the fund's stake to an even 7 million shares.\nScratching your head as to why a successful money manager is buying into an old-school retailer? The answer looks to be Macy's, thus far, solid execution on its three-year Polaris strategy. In no particular order, this strategy includes:\n\nClosing underperforming stores and reducing corporate and store-level staff to cut expenses.\nEmphasizing digital sales channels, which are a high-growth opportunity for the company until the pandemic ends (and perhaps well after).\nIncreasing customer engagement through its loyalty rewards program.\nFocusing its efforts of a small number of higher-margin private brands.\n\nAlthough Macy's has challenges to overcome, such as continuing to pay down more than $6 billion in debt, the initial results show its digitization and branding efforts are paying off. The company ended September with 4.4 million new customers, up 28% from the comparable period in 2019 (i.e., before the pandemic). Additionally, 33% of net sales derived online, up from 23% in Q3 2019.  If these arrows continue to point higher, Tepper may have found himself a bargain.\nImage source: Getty Images.\nIsrael Englander (Millennium Management): AT&T\nLike Ken Griffin, billionaire Israel Englander is a big fan of utilizing put and call options to maximize returns for his fund, Millennium Management. However, the big buy in the third quarter was stodgy telecom giant AT&T (NYSE:T). Englander's fund bought up close to 11.2 million shares, which increased its stake by 165% from the sequential second quarter.\nSimilar to Coca-Cola, buying AT&T is a play on value and stability in a very pricey market. For the time being, it's paying out an inflation-topping 8.6% yield and can be purchased for a little north of 7 times Wall Street's estimated earnings per share this year.\nBut what might have wet Englander's whistle is AT&T's plan to spin off its content arm, WarnerMedia, and combine it with Discovery. Combining forces will save more than $3 billion in annual costs and vastly improve original and sports programming options for streaming customers. Most importantly, it'll allow AT&T to reduce its debt (and its dividend, as well) and focus on growing its wireless business with the ongoing rollout of 5G infrastructure.","news_type":1},"isVote":1,"tweetType":1,"viewCount":713,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609263789,"gmtCreate":1638286545384,"gmtModify":1638286545384,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609263789","repostId":"1181644709","repostType":4,"isVote":1,"tweetType":1,"viewCount":388,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609263541,"gmtCreate":1638286522611,"gmtModify":1638286522611,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"That's great","listText":"That's great","text":"That's great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609263541","repostId":"2187580541","repostType":4,"isVote":1,"tweetType":1,"viewCount":415,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609263365,"gmtCreate":1638286470568,"gmtModify":1638286470621,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oh wells","listText":"Oh wells","text":"Oh wells","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609263365","repostId":"1190156196","repostType":4,"repost":{"id":"1190156196","pubTimestamp":1638242388,"share":"https://www.laohu8.com/m/news/1190156196?lang=&edition=full","pubTime":"2021-11-30 11:19","market":"us","language":"en","title":"5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1190156196","media":"InvestorPlace","summary":"Here are the stocks to watch as the omicron variant gives rise to a new vaccine race","content":"<p>Here are the stocks to watch as the omicron variant gives rise to a new vaccine race</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/537aabc5fd6c7ca4f614ce1b37dc0a75\" tg-width=\"1024\" tg-height=\"576\" width=\"100%\" height=\"auto\"><span>Source: Shutterstock</span></p>\n<p>As Black Friday approached, most investors were speculating on what the supply chain crisis would mean for the year’s biggest shopping holiday. By the time shopping began, though, most minds were on another news story. A new Covid-19 variant had been detected in South Africa and it was quickly spreading to Europe. Labeled the omicron variant, this new Covid-19 strain poses a threat to the pandemic recovery story. Perhaps most importantly, we don’t yet know how big that threat is. Scientists haveindicatedthat it will take at least a few weeks for them to assess the effectiveness of vaccines against the new variant, which features multiple mutations. As investors ponder what this means for markets, focus has shifted to one specific question: What does this mean for vaccine stocks?</p>\n<p>Investors have expressed concern at what the the emergence of a new variant may mean for markets. It bears noting, though, that such a scenario creates a new opportunity for vaccine stocks, specifically for a new company to pull into the lead.</p>\n<p>While&nbsp;<b>Pfizer’s</b>(NYSE:<b><u>PFE</u></b>)&nbsp;success in&nbsp;producing&nbsp;a vaccine approved for children has helped it maintain a lead over its competitors, other companies recognize the need for further innovation within the vaccine space. Scientists and researchers have yet to reach a conclusion as to how the new variant will react to current vaccines, but the companies producing them are already working around the clock.</p>\n<p>Many vaccine stocks were trending this morning as the omicron variant dominated news coverage. Let’s take a look at what the most prominent vaccine producers are saying and when we can expect to see progress.</p>\n<ul>\n <li><b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>)</li>\n <li><b>Pfizer</b>(NYSE:<b><u>PFE</u></b>)</li>\n <li><b>BioNTech</b>&nbsp;(NASDAQ:<b><u>BNTX</u></b>)</li>\n <li><b>Johnson &amp; Johnson</b>(NYSE:<b><u>JNJ</u></b>)</li>\n <li><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>)</li>\n</ul>\n<p><b>Moderna (MRNA)</b></p>\n<p>Moderna was one of the first companies to have its executive team discuss address the omicron variant.</p>\n<p>On Sunday, CMO Paul Burton spoke to<i>BBC’s</i>Andrew Marr and said Moderna was hoping to see clinical trials of an omicron-specific booster begin within60 to 90 days. CEO Stephane Bancel recentlyspoketo<i>CNBC’s</i>“Squawk Box” on the topic of an omicron- targeting vaccine. While he stated that it will likely take months for the company to develop, produce and ship a vaccine with the ability to target that specific variant, he noted that a booster shot containing a higher 100-microgram dose could be made available much sooner.</p>\n<p>Bancel also floated the possibility of administering higher doses of the current vaccines to particularly high-risk patients, such as those in the elderly or immunocompromised categories.</p>\n<p>This talk of an effective booster that could take on the new variant has sent MRNA stock shooting up today. As of this writing, vaccine stocks are having a good day and Moderna has risen by more than 10%. Today’s gains have put it up by more than 30% for the past five days.</p>\n<p>While&nbsp;the head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.</p>\n<p>\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times&nbsp;in an interview.</p>\n<p>\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"</p>\n<p><b>Pfizer (PFE)</b></p>\n<p>No pharmaceutical company has received as much positive press for its vaccine innovations as Pfizer. Earlier this month, CEO Albert Bourla wasrecommended by one&nbsp;<i>InvestorPlace</i>&nbsp;contributorfor CEO of the year.</p>\n<p>The industry leader alsodiscussedthe new variant earlier today, stating that he believed that Pfizer’s Covid-19 pill would prove effective against it. He noted that the treatment method was designed with the thought process that most virus mutations were coming in spikes, exactly what we are seeing so far from the omicron variant. This gives him, he said, a “very high level of confidence” that the oral treatment, Paxlovid, will prove well-suited to help patients with the new Covid-19 strain.</p>\n<p>Clinical trials have found that when Paxlovid is taken with HIV drug ritonavir, it reduces hospitalization and death by 89% if taken within three days after symptoms have begun.</p>\n<p>While Bourla is still not able to offer much on the effectiveness of the company’s two-dose vaccine against the new variant, he experts it to offer at least some protection. He also said that Pfizer is already at work on a new vaccine and that it produced a DNA template on Friday, speculating that it could be ready within 100 days.</p>\n<p>It is worth noting that Pfizer has been able to create vaccines for previous variants in that timeframe but did not end up having to administer them, as the previously distributed vaccines remained effective.</p>\n<p><b>BioNTech (BNTX)</b></p>\n<p>Pfizer’s original vaccine partner isn’t missing a beat, either.</p>\n<p>The German biotech innovatortold<i>Business Insider</i>that it is already at work on the development of an adapted vaccine to combat the omicron variant. According to the company’s spokespeople, the first steps of such a process “overlap with the research necessary” to evaluate the necessity of a new shot. This approach should enable its research team to move forward as quickly as possible.</p>\n<p>Like its competitors, BioNTech expects to acquire the data necessary to determine next steps in roughly two weeks, as medical researchers rush to examine new cases. In an attempt to keep the process as efficient as possible, the company is already testing its existing vaccine doses. Like Pfizer, it claims that it will be able to ship out this adapted vaccine within 100 days should it prove necessary.</p>\n<p>Like other vaccine stocks, BNTX is having a good day as speculation regarding the vaccine mounts. Shares are up almost 4% as of this writing. Not unlike its competitor Moderna, BioNTech is up almost 20% for the week after seeing a period of mostly flatlining. Earlier this Summer,<i>InvestorPlace</i>&nbsp;analyst Louis Navelliercalledit a better buy among vaccine stocks than Pfizer.</p>\n<p><b>Johnson &amp; Johnson (JNJ)</b></p>\n<p>Like its competitors, Johnson &amp; Johnson is already at work on ways to combat the new variant. Still waiting on further data, though, the company hasstatedit “will progress [its new vaccine] into clinical studies if needed.”</p>\n<p>Mathai Mammen, global head of research and development at J&amp;J subsidiary Janssen Pharmaceuticals, says that the company remains confident in the “robust humoral and cell-mediated responses” that its original vaccine has elicited in patients to date, giving the company confidence in its ability to adapt its current vaccine to handle the omicron variant.</p>\n<p>Mammen added that the company has already begun work on a new vaccine for exactly that purpose and will “rapidly progress into clinical trails” if it is deemed necessary. It has beenreportedthat testing has already begun.</p>\n<p><b>Novavax (NVAX)</b></p>\n<p>A later player to the vaccine race, Novavax hasn’t had the same success in the U.S. as Pfizer or Moderna.</p>\n<p>However, the company recognizes it has a chance to make up the lost ground. In fact, it is already working to develop a vaccine to combat the omicron variant. Novavax hasstatedthat its vaccine will contain the mutated spikes that have experts worried about the variant, thereby enabling recipients to develop necessary immune responses. Its spokespeople have also stated that the testing and developing of the new vaccine will likely take “a few weeks.”</p>\n<p>While Novavax has not filed for approval for its initial Covid-19 in the U.S. yet, it received the green light from regulators in both Indonesia and the Philippines.</p>\n<p>As&nbsp;<i>InvestorPlace</i>&nbsp;Assistant News Writer&nbsp;Eddie Pan&nbsp;reported&nbsp;this morning, NVAX is a name to watch among vaccine stocks as speculation mounts. While no one is likely to know too much for at least two weeks, companies aren’t wasting any time in building on their vaccine innovations in attempt to pull ahead in the vaccine race. Novavax may not have garnered U.S. authorization yet, but it has risen to prominence by way of its global vaccine distribution work, an edge that earned it ahigh rankingamong second-shot vaccine stocks to buy.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 11:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Here are the stocks to watch as the omicron variant gives rise to a new vaccine race\nSource: Shutterstock\nAs Black Friday approached, most investors were speculating on what the supply chain crisis ...</p>\n\n<a href=\"https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"source_url":"https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190156196","content_text":"Here are the stocks to watch as the omicron variant gives rise to a new vaccine race\nSource: Shutterstock\nAs Black Friday approached, most investors were speculating on what the supply chain crisis would mean for the year’s biggest shopping holiday. By the time shopping began, though, most minds were on another news story. A new Covid-19 variant had been detected in South Africa and it was quickly spreading to Europe. Labeled the omicron variant, this new Covid-19 strain poses a threat to the pandemic recovery story. Perhaps most importantly, we don’t yet know how big that threat is. Scientists haveindicatedthat it will take at least a few weeks for them to assess the effectiveness of vaccines against the new variant, which features multiple mutations. As investors ponder what this means for markets, focus has shifted to one specific question: What does this mean for vaccine stocks?\nInvestors have expressed concern at what the the emergence of a new variant may mean for markets. It bears noting, though, that such a scenario creates a new opportunity for vaccine stocks, specifically for a new company to pull into the lead.\nWhile Pfizer’s(NYSE:PFE) success in producing a vaccine approved for children has helped it maintain a lead over its competitors, other companies recognize the need for further innovation within the vaccine space. Scientists and researchers have yet to reach a conclusion as to how the new variant will react to current vaccines, but the companies producing them are already working around the clock.\nMany vaccine stocks were trending this morning as the omicron variant dominated news coverage. Let’s take a look at what the most prominent vaccine producers are saying and when we can expect to see progress.\n\nModerna(NASDAQ:MRNA)\nPfizer(NYSE:PFE)\nBioNTech (NASDAQ:BNTX)\nJohnson & Johnson(NYSE:JNJ)\nNovavax(NASDAQ:NVAX)\n\nModerna (MRNA)\nModerna was one of the first companies to have its executive team discuss address the omicron variant.\nOn Sunday, CMO Paul Burton spoke toBBC’sAndrew Marr and said Moderna was hoping to see clinical trials of an omicron-specific booster begin within60 to 90 days. CEO Stephane Bancel recentlyspoketoCNBC’s“Squawk Box” on the topic of an omicron- targeting vaccine. While he stated that it will likely take months for the company to develop, produce and ship a vaccine with the ability to target that specific variant, he noted that a booster shot containing a higher 100-microgram dose could be made available much sooner.\nBancel also floated the possibility of administering higher doses of the current vaccines to particularly high-risk patients, such as those in the elderly or immunocompromised categories.\nThis talk of an effective booster that could take on the new variant has sent MRNA stock shooting up today. As of this writing, vaccine stocks are having a good day and Moderna has risen by more than 10%. Today’s gains have put it up by more than 30% for the past five days.\nWhile the head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.\n\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times in an interview.\n\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"\nPfizer (PFE)\nNo pharmaceutical company has received as much positive press for its vaccine innovations as Pfizer. Earlier this month, CEO Albert Bourla wasrecommended by one InvestorPlace contributorfor CEO of the year.\nThe industry leader alsodiscussedthe new variant earlier today, stating that he believed that Pfizer’s Covid-19 pill would prove effective against it. He noted that the treatment method was designed with the thought process that most virus mutations were coming in spikes, exactly what we are seeing so far from the omicron variant. This gives him, he said, a “very high level of confidence” that the oral treatment, Paxlovid, will prove well-suited to help patients with the new Covid-19 strain.\nClinical trials have found that when Paxlovid is taken with HIV drug ritonavir, it reduces hospitalization and death by 89% if taken within three days after symptoms have begun.\nWhile Bourla is still not able to offer much on the effectiveness of the company’s two-dose vaccine against the new variant, he experts it to offer at least some protection. He also said that Pfizer is already at work on a new vaccine and that it produced a DNA template on Friday, speculating that it could be ready within 100 days.\nIt is worth noting that Pfizer has been able to create vaccines for previous variants in that timeframe but did not end up having to administer them, as the previously distributed vaccines remained effective.\nBioNTech (BNTX)\nPfizer’s original vaccine partner isn’t missing a beat, either.\nThe German biotech innovatortoldBusiness Insiderthat it is already at work on the development of an adapted vaccine to combat the omicron variant. According to the company’s spokespeople, the first steps of such a process “overlap with the research necessary” to evaluate the necessity of a new shot. This approach should enable its research team to move forward as quickly as possible.\nLike its competitors, BioNTech expects to acquire the data necessary to determine next steps in roughly two weeks, as medical researchers rush to examine new cases. In an attempt to keep the process as efficient as possible, the company is already testing its existing vaccine doses. Like Pfizer, it claims that it will be able to ship out this adapted vaccine within 100 days should it prove necessary.\nLike other vaccine stocks, BNTX is having a good day as speculation regarding the vaccine mounts. Shares are up almost 4% as of this writing. Not unlike its competitor Moderna, BioNTech is up almost 20% for the week after seeing a period of mostly flatlining. Earlier this Summer,InvestorPlace analyst Louis Navelliercalledit a better buy among vaccine stocks than Pfizer.\nJohnson & Johnson (JNJ)\nLike its competitors, Johnson & Johnson is already at work on ways to combat the new variant. Still waiting on further data, though, the company hasstatedit “will progress [its new vaccine] into clinical studies if needed.”\nMathai Mammen, global head of research and development at J&J subsidiary Janssen Pharmaceuticals, says that the company remains confident in the “robust humoral and cell-mediated responses” that its original vaccine has elicited in patients to date, giving the company confidence in its ability to adapt its current vaccine to handle the omicron variant.\nMammen added that the company has already begun work on a new vaccine for exactly that purpose and will “rapidly progress into clinical trails” if it is deemed necessary. It has beenreportedthat testing has already begun.\nNovavax (NVAX)\nA later player to the vaccine race, Novavax hasn’t had the same success in the U.S. as Pfizer or Moderna.\nHowever, the company recognizes it has a chance to make up the lost ground. In fact, it is already working to develop a vaccine to combat the omicron variant. Novavax hasstatedthat its vaccine will contain the mutated spikes that have experts worried about the variant, thereby enabling recipients to develop necessary immune responses. Its spokespeople have also stated that the testing and developing of the new vaccine will likely take “a few weeks.”\nWhile Novavax has not filed for approval for its initial Covid-19 in the U.S. yet, it received the green light from regulators in both Indonesia and the Philippines.\nAs InvestorPlace Assistant News Writer Eddie Pan reported this morning, NVAX is a name to watch among vaccine stocks as speculation mounts. While no one is likely to know too much for at least two weeks, companies aren’t wasting any time in building on their vaccine innovations in attempt to pull ahead in the vaccine race. Novavax may not have garnered U.S. authorization yet, but it has risen to prominence by way of its global vaccine distribution work, an edge that earned it ahigh rankingamong second-shot vaccine stocks to buy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":769,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600545182,"gmtCreate":1638179310187,"gmtModify":1638180396728,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oo","listText":"Oo","text":"Oo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600545182","repostId":"1193304775","repostType":4,"isVote":1,"tweetType":1,"viewCount":298,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874831562,"gmtCreate":1637754053562,"gmtModify":1637754058082,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oo","listText":"Oo","text":"Oo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874831562","repostId":"1199806578","repostType":2,"isVote":1,"tweetType":1,"viewCount":416,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872060771,"gmtCreate":1637376084068,"gmtModify":1637376084211,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>BBelieve in it","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>BBelieve in it","text":"$NIO Inc.(NIO)$BBelieve in it","images":[{"img":"https://static.tigerbbs.com/32398208a6a07772e95d13e64149542c","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/872060771","isVote":1,"tweetType":1,"viewCount":511,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":872060131,"gmtCreate":1637376029766,"gmtModify":1637376029924,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Not earning much as compared to prev record but all good","listText":"Not earning much as compared to prev record but all good","text":"Not earning much as compared to prev record but all good","images":[{"img":"https://static.tigerbbs.com/97c01b15c123070a68e19134ae90eee1","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872060131","isVote":1,"tweetType":1,"viewCount":577,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":876947797,"gmtCreate":1637253265603,"gmtModify":1637253266704,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SEV\">$Sono Group N.V.(SEV)$</a>😅","listText":"<a href=\"https://laohu8.com/S/SEV\">$Sono Group N.V.(SEV)$</a>😅","text":"$Sono Group N.V.(SEV)$😅","images":[{"img":"https://static.tigerbbs.com/150f48431a71c41857a882bc49b29bf5","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876947797","isVote":1,"tweetType":1,"viewCount":376,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":876903747,"gmtCreate":1637247444421,"gmtModify":1637247444421,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"This is nice ☺️","listText":"This is nice ☺️","text":"This is nice ☺️","images":[{"img":"https://static.tigerbbs.com/3fdfd57e4cd4967c6a122cff43245640","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876903747","isVote":1,"tweetType":1,"viewCount":574,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":878686271,"gmtCreate":1637190219247,"gmtModify":1637190219247,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SEV\">$Sono Group N.V.(SEV)$</a>ttought that wouldn't make it&nbsp;[得意]&nbsp;","listText":"<a href=\"https://laohu8.com/S/SEV\">$Sono Group N.V.(SEV)$</a>ttought that wouldn't make it&nbsp;[得意]&nbsp;","text":"$Sono Group N.V.(SEV)$ttought that wouldn't make it [得意]","images":[{"img":"https://static.tigerbbs.com/ad5b5c16d3d74044165374a4b39b85da","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878686271","isVote":1,"tweetType":1,"viewCount":115,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":878881011,"gmtCreate":1637165457292,"gmtModify":1637165457292,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Up up and away 🎈🎈🎈","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Up up and away 🎈🎈🎈","text":"$AMC Entertainment(AMC)$Up up and away 🎈🎈🎈","images":[{"img":"https://static.tigerbbs.com/1ff4df647da9a225a664bffb876766df","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/878881011","isVote":1,"tweetType":1,"viewCount":215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":878800652,"gmtCreate":1637162463472,"gmtModify":1637162463521,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[财迷]&nbsp;","listText":"[财迷]&nbsp;","text":"[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878800652","repostId":"1199355122","repostType":2,"repost":{"id":"1199355122","pubTimestamp":1637150344,"share":"https://www.laohu8.com/m/news/1199355122?lang=&edition=full","pubTime":"2021-11-17 19:59","market":"us","language":"en","title":"25 Stocks Moving in Wednesday's Pre-Market Session","url":"https://stock-news.laohu8.com/highlight/detail?id=1199355122","media":"Benzinga","summary":"Gainers\n\n17 Education & Technology Group Inc. rose 283.5% to $3.16 in pre-market trading. 17 Educati","content":"<p><b>Gainers</b></p>\n<ul>\n <li><b>17 Education &amp; Technology Group Inc.</b>&nbsp;rose 283.5% to $3.16 in pre-market trading. 17 Education &amp; Technology, earlier during the month, reported a $10 million buyback program.</li>\n <li><b>Rockwell Medical, Inc.</b>&nbsp;rose 58.6% to $0.7632 in pre-market trading after the company announced results from a study demonstrated no drug-drug interaction between ferric pyrophosphate citrate and unfractionated heparin.</li>\n <li><b>SPI Energy Co., Ltd.</b>&nbsp;shares rose 20% to $7.38 in pre-market trading after gaining 9% on Tuesday.</li>\n <li><b>Asia Pacific Wire &amp; Cable Corporation Limited</b>&nbsp;rose 19% to $3.19 in pre-market trading after the company posted a narrower loss for the first half of the year.</li>\n <li><b>Progenity, Inc.</b>&nbsp;rose 14.7% to $5.55 in pre-market trading. Progenity shares jumped over 39% on Tuesday amid continued retail investor interest on social media.</li>\n <li><b>Mullen Automotive, Inc.</b>&nbsp;rose 12.6% to $14.80 in pre-market trading after gaining 11% on Tuesday.</li>\n <li><b>Canoo Inc.</b>&nbsp;rose 12.6% to $11.77 in pre-market trading. Canoo shares surged around 24% on Tuesday after the company said it will accelerate its advanced manufacturing production in the US to begin before Q4.</li>\n <li><b>Lucid Group, Inc</b>&nbsp;shares rose 11.1% to $61.82 in pre-market trading. Lucid Group shares jumped 24% on Tuesday after the company announced Q3 financial results.</li>\n <li><b>Camber Energy, Inc.</b>&nbsp;rose 10.8% to $1.23 in pre-market trading after gaining around 7% on Tuesday.</li>\n <li><b>Bone Biologics Corporation</b>&nbsp;rose 10.6% to $4.28 in pre-market trading. Bone Biologics recently reported a Q3 loss of $0.17 per share.</li>\n <li><b>Vir Biotechnology, Inc.</b>&nbsp;shares rose 9.6% to $36.62 in pre-market trading. GlaxoSmithKline and Vir Biotechnology recently announced topline data from COMET-TAIL Phase 3 trial evaluating sotrovimab delivered via Intramuscular (IM) administration compared to IV administration in high-risk COVID-19 patients.</li>\n <li><b>Chembio Diagnostics, Inc.</b>&nbsp;rose 8.3% to $2.23 in pre-market trading after the company announced the submission of an Emergency Use Authorization application to the FDA for the new DPP SARS-CoV-2 Antigen test.</li>\n <li><b>Lion Group Holding Ltd.</b>&nbsp;rose 7.5% to $2.29 in pre-market trading after gaining 5% on Tuesday.</li>\n <li><b>Innoviz Technologies Ltd.</b>&nbsp;rose 7.2% to $6.35 in pre-market trading. Innoviz Technologies, last week, reported a Q3 loss of $0.20 per share on sales of $2.10 million.</li>\n</ul>\n<p><b>Losers</b></p>\n<ul>\n <li><b>Cyclo Therapeutics, Inc.</b>&nbsp;fell 14.2% to $6.30 in pre-market trading after the company reported pricing of $11.7 million underwritten public offering of common stock.</li>\n <li><b>Atea Pharmaceuticals, Inc.</b>&nbsp;fell 12.7% to $9.92 in pre-market trading after Roche Holding AG terminated a partnership with the company to jointly develop a COVID-19 antiviral pill.</li>\n <li><b>SOC Telemed, Inc.</b>&nbsp;shares fell 11.5% to $2.63 in pre-market trading. SOC Telemed, last week, reported better-than-expected Q3 EPS and sales results and raised FY21 guidance.</li>\n <li><b>DLocal Limited</b>&nbsp;shares fell 8.7% to $42.90 in pre-market trading after reporting downbeat quarterly earnings.</li>\n <li><b>Creative Realities, Inc.</b>&nbsp;fell 8.2% to $2.25 in pre-market trading. The company recently posted downbeat quarterly sales.</li>\n <li><b>Altamira Therapeutics Ltd.</b>&nbsp;shares fell 8.1% to $2.16 in pre-market trading. Altamira Therapeutics recently announced efficacy data from testing its Bentrio nasal spray in vitro against the Delta variant of the SARS-CoV-2 virus.</li>\n <li><b>ReTo Eco-Solutions, Inc.</b>&nbsp;shares fell 8.1% to $2.51 in pre-market trading after jumping over 48% on Tuesday.</li>\n <li><b>StoneCo Ltd.</b>&nbsp;fell 7.9% to $29.16 in pre-market trading after the company reported Q3 results.</li>\n <li><b>Second Sight Medical Products, Inc.</b>&nbsp;fell 7.3% to $3.16 in pre-market trading after jumping 25% on Tuesday.</li>\n <li><b>Verb Technology Company, Inc.</b>&nbsp;shares fell 6.4% to $1.89 in pre-market trading after the company reported at the market equity offering program.</li>\n <li><b>iQIYI, Inc.</b>&nbsp;fell 5% to $8.16 in pre-market trading following Q3 results.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>25 Stocks Moving in Wednesday's Pre-Market Session</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n25 Stocks Moving in Wednesday's Pre-Market Session\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-17 19:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/11/24141959/25-stocks-moving-in-wednesdays-pre-market-session><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gainers\n\n17 Education & Technology Group Inc. rose 283.5% to $3.16 in pre-market trading. 17 Education & Technology, earlier during the month, reported a $10 million buyback program.\nRockwell Medical,...</p>\n\n<a href=\"https://www.benzinga.com/news/21/11/24141959/25-stocks-moving-in-wednesdays-pre-market-session\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LCID":"Lucid Group Inc","GOEV":"Canoo Inc.","IQ":"爱奇艺"},"source_url":"https://www.benzinga.com/news/21/11/24141959/25-stocks-moving-in-wednesdays-pre-market-session","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199355122","content_text":"Gainers\n\n17 Education & Technology Group Inc. rose 283.5% to $3.16 in pre-market trading. 17 Education & Technology, earlier during the month, reported a $10 million buyback program.\nRockwell Medical, Inc. rose 58.6% to $0.7632 in pre-market trading after the company announced results from a study demonstrated no drug-drug interaction between ferric pyrophosphate citrate and unfractionated heparin.\nSPI Energy Co., Ltd. shares rose 20% to $7.38 in pre-market trading after gaining 9% on Tuesday.\nAsia Pacific Wire & Cable Corporation Limited rose 19% to $3.19 in pre-market trading after the company posted a narrower loss for the first half of the year.\nProgenity, Inc. rose 14.7% to $5.55 in pre-market trading. Progenity shares jumped over 39% on Tuesday amid continued retail investor interest on social media.\nMullen Automotive, Inc. rose 12.6% to $14.80 in pre-market trading after gaining 11% on Tuesday.\nCanoo Inc. rose 12.6% to $11.77 in pre-market trading. Canoo shares surged around 24% on Tuesday after the company said it will accelerate its advanced manufacturing production in the US to begin before Q4.\nLucid Group, Inc shares rose 11.1% to $61.82 in pre-market trading. Lucid Group shares jumped 24% on Tuesday after the company announced Q3 financial results.\nCamber Energy, Inc. rose 10.8% to $1.23 in pre-market trading after gaining around 7% on Tuesday.\nBone Biologics Corporation rose 10.6% to $4.28 in pre-market trading. Bone Biologics recently reported a Q3 loss of $0.17 per share.\nVir Biotechnology, Inc. shares rose 9.6% to $36.62 in pre-market trading. GlaxoSmithKline and Vir Biotechnology recently announced topline data from COMET-TAIL Phase 3 trial evaluating sotrovimab delivered via Intramuscular (IM) administration compared to IV administration in high-risk COVID-19 patients.\nChembio Diagnostics, Inc. rose 8.3% to $2.23 in pre-market trading after the company announced the submission of an Emergency Use Authorization application to the FDA for the new DPP SARS-CoV-2 Antigen test.\nLion Group Holding Ltd. rose 7.5% to $2.29 in pre-market trading after gaining 5% on Tuesday.\nInnoviz Technologies Ltd. rose 7.2% to $6.35 in pre-market trading. Innoviz Technologies, last week, reported a Q3 loss of $0.20 per share on sales of $2.10 million.\n\nLosers\n\nCyclo Therapeutics, Inc. fell 14.2% to $6.30 in pre-market trading after the company reported pricing of $11.7 million underwritten public offering of common stock.\nAtea Pharmaceuticals, Inc. fell 12.7% to $9.92 in pre-market trading after Roche Holding AG terminated a partnership with the company to jointly develop a COVID-19 antiviral pill.\nSOC Telemed, Inc. shares fell 11.5% to $2.63 in pre-market trading. SOC Telemed, last week, reported better-than-expected Q3 EPS and sales results and raised FY21 guidance.\nDLocal Limited shares fell 8.7% to $42.90 in pre-market trading after reporting downbeat quarterly earnings.\nCreative Realities, Inc. fell 8.2% to $2.25 in pre-market trading. The company recently posted downbeat quarterly sales.\nAltamira Therapeutics Ltd. shares fell 8.1% to $2.16 in pre-market trading. Altamira Therapeutics recently announced efficacy data from testing its Bentrio nasal spray in vitro against the Delta variant of the SARS-CoV-2 virus.\nReTo Eco-Solutions, Inc. shares fell 8.1% to $2.51 in pre-market trading after jumping over 48% on Tuesday.\nStoneCo Ltd. fell 7.9% to $29.16 in pre-market trading after the company reported Q3 results.\nSecond Sight Medical Products, Inc. fell 7.3% to $3.16 in pre-market trading after jumping 25% on Tuesday.\nVerb Technology Company, Inc. shares fell 6.4% to $1.89 in pre-market trading after the company reported at the market equity offering program.\niQIYI, Inc. fell 5% to $8.16 in pre-market trading following Q3 results.","news_type":1},"isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":609263365,"gmtCreate":1638286470568,"gmtModify":1638286470621,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oh wells","listText":"Oh wells","text":"Oh wells","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609263365","repostId":"1190156196","repostType":4,"repost":{"id":"1190156196","pubTimestamp":1638242388,"share":"https://www.laohu8.com/m/news/1190156196?lang=&edition=full","pubTime":"2021-11-30 11:19","market":"us","language":"en","title":"5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1190156196","media":"InvestorPlace","summary":"Here are the stocks to watch as the omicron variant gives rise to a new vaccine race","content":"<p>Here are the stocks to watch as the omicron variant gives rise to a new vaccine race</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/537aabc5fd6c7ca4f614ce1b37dc0a75\" tg-width=\"1024\" tg-height=\"576\" width=\"100%\" height=\"auto\"><span>Source: Shutterstock</span></p>\n<p>As Black Friday approached, most investors were speculating on what the supply chain crisis would mean for the year’s biggest shopping holiday. By the time shopping began, though, most minds were on another news story. A new Covid-19 variant had been detected in South Africa and it was quickly spreading to Europe. Labeled the omicron variant, this new Covid-19 strain poses a threat to the pandemic recovery story. Perhaps most importantly, we don’t yet know how big that threat is. Scientists haveindicatedthat it will take at least a few weeks for them to assess the effectiveness of vaccines against the new variant, which features multiple mutations. As investors ponder what this means for markets, focus has shifted to one specific question: What does this mean for vaccine stocks?</p>\n<p>Investors have expressed concern at what the the emergence of a new variant may mean for markets. It bears noting, though, that such a scenario creates a new opportunity for vaccine stocks, specifically for a new company to pull into the lead.</p>\n<p>While&nbsp;<b>Pfizer’s</b>(NYSE:<b><u>PFE</u></b>)&nbsp;success in&nbsp;producing&nbsp;a vaccine approved for children has helped it maintain a lead over its competitors, other companies recognize the need for further innovation within the vaccine space. Scientists and researchers have yet to reach a conclusion as to how the new variant will react to current vaccines, but the companies producing them are already working around the clock.</p>\n<p>Many vaccine stocks were trending this morning as the omicron variant dominated news coverage. Let’s take a look at what the most prominent vaccine producers are saying and when we can expect to see progress.</p>\n<ul>\n <li><b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>)</li>\n <li><b>Pfizer</b>(NYSE:<b><u>PFE</u></b>)</li>\n <li><b>BioNTech</b>&nbsp;(NASDAQ:<b><u>BNTX</u></b>)</li>\n <li><b>Johnson &amp; Johnson</b>(NYSE:<b><u>JNJ</u></b>)</li>\n <li><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>)</li>\n</ul>\n<p><b>Moderna (MRNA)</b></p>\n<p>Moderna was one of the first companies to have its executive team discuss address the omicron variant.</p>\n<p>On Sunday, CMO Paul Burton spoke to<i>BBC’s</i>Andrew Marr and said Moderna was hoping to see clinical trials of an omicron-specific booster begin within60 to 90 days. CEO Stephane Bancel recentlyspoketo<i>CNBC’s</i>“Squawk Box” on the topic of an omicron- targeting vaccine. While he stated that it will likely take months for the company to develop, produce and ship a vaccine with the ability to target that specific variant, he noted that a booster shot containing a higher 100-microgram dose could be made available much sooner.</p>\n<p>Bancel also floated the possibility of administering higher doses of the current vaccines to particularly high-risk patients, such as those in the elderly or immunocompromised categories.</p>\n<p>This talk of an effective booster that could take on the new variant has sent MRNA stock shooting up today. As of this writing, vaccine stocks are having a good day and Moderna has risen by more than 10%. Today’s gains have put it up by more than 30% for the past five days.</p>\n<p>While&nbsp;the head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.</p>\n<p>\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times&nbsp;in an interview.</p>\n<p>\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"</p>\n<p><b>Pfizer (PFE)</b></p>\n<p>No pharmaceutical company has received as much positive press for its vaccine innovations as Pfizer. Earlier this month, CEO Albert Bourla wasrecommended by one&nbsp;<i>InvestorPlace</i>&nbsp;contributorfor CEO of the year.</p>\n<p>The industry leader alsodiscussedthe new variant earlier today, stating that he believed that Pfizer’s Covid-19 pill would prove effective against it. He noted that the treatment method was designed with the thought process that most virus mutations were coming in spikes, exactly what we are seeing so far from the omicron variant. This gives him, he said, a “very high level of confidence” that the oral treatment, Paxlovid, will prove well-suited to help patients with the new Covid-19 strain.</p>\n<p>Clinical trials have found that when Paxlovid is taken with HIV drug ritonavir, it reduces hospitalization and death by 89% if taken within three days after symptoms have begun.</p>\n<p>While Bourla is still not able to offer much on the effectiveness of the company’s two-dose vaccine against the new variant, he experts it to offer at least some protection. He also said that Pfizer is already at work on a new vaccine and that it produced a DNA template on Friday, speculating that it could be ready within 100 days.</p>\n<p>It is worth noting that Pfizer has been able to create vaccines for previous variants in that timeframe but did not end up having to administer them, as the previously distributed vaccines remained effective.</p>\n<p><b>BioNTech (BNTX)</b></p>\n<p>Pfizer’s original vaccine partner isn’t missing a beat, either.</p>\n<p>The German biotech innovatortold<i>Business Insider</i>that it is already at work on the development of an adapted vaccine to combat the omicron variant. According to the company’s spokespeople, the first steps of such a process “overlap with the research necessary” to evaluate the necessity of a new shot. This approach should enable its research team to move forward as quickly as possible.</p>\n<p>Like its competitors, BioNTech expects to acquire the data necessary to determine next steps in roughly two weeks, as medical researchers rush to examine new cases. In an attempt to keep the process as efficient as possible, the company is already testing its existing vaccine doses. Like Pfizer, it claims that it will be able to ship out this adapted vaccine within 100 days should it prove necessary.</p>\n<p>Like other vaccine stocks, BNTX is having a good day as speculation regarding the vaccine mounts. Shares are up almost 4% as of this writing. Not unlike its competitor Moderna, BioNTech is up almost 20% for the week after seeing a period of mostly flatlining. Earlier this Summer,<i>InvestorPlace</i>&nbsp;analyst Louis Navelliercalledit a better buy among vaccine stocks than Pfizer.</p>\n<p><b>Johnson &amp; Johnson (JNJ)</b></p>\n<p>Like its competitors, Johnson &amp; Johnson is already at work on ways to combat the new variant. Still waiting on further data, though, the company hasstatedit “will progress [its new vaccine] into clinical studies if needed.”</p>\n<p>Mathai Mammen, global head of research and development at J&amp;J subsidiary Janssen Pharmaceuticals, says that the company remains confident in the “robust humoral and cell-mediated responses” that its original vaccine has elicited in patients to date, giving the company confidence in its ability to adapt its current vaccine to handle the omicron variant.</p>\n<p>Mammen added that the company has already begun work on a new vaccine for exactly that purpose and will “rapidly progress into clinical trails” if it is deemed necessary. It has beenreportedthat testing has already begun.</p>\n<p><b>Novavax (NVAX)</b></p>\n<p>A later player to the vaccine race, Novavax hasn’t had the same success in the U.S. as Pfizer or Moderna.</p>\n<p>However, the company recognizes it has a chance to make up the lost ground. In fact, it is already working to develop a vaccine to combat the omicron variant. Novavax hasstatedthat its vaccine will contain the mutated spikes that have experts worried about the variant, thereby enabling recipients to develop necessary immune responses. Its spokespeople have also stated that the testing and developing of the new vaccine will likely take “a few weeks.”</p>\n<p>While Novavax has not filed for approval for its initial Covid-19 in the U.S. yet, it received the green light from regulators in both Indonesia and the Philippines.</p>\n<p>As&nbsp;<i>InvestorPlace</i>&nbsp;Assistant News Writer&nbsp;Eddie Pan&nbsp;reported&nbsp;this morning, NVAX is a name to watch among vaccine stocks as speculation mounts. While no one is likely to know too much for at least two weeks, companies aren’t wasting any time in building on their vaccine innovations in attempt to pull ahead in the vaccine race. Novavax may not have garnered U.S. authorization yet, but it has risen to prominence by way of its global vaccine distribution work, an edge that earned it ahigh rankingamong second-shot vaccine stocks to buy.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 11:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Here are the stocks to watch as the omicron variant gives rise to a new vaccine race\nSource: Shutterstock\nAs Black Friday approached, most investors were speculating on what the supply chain crisis ...</p>\n\n<a href=\"https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"source_url":"https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190156196","content_text":"Here are the stocks to watch as the omicron variant gives rise to a new vaccine race\nSource: Shutterstock\nAs Black Friday approached, most investors were speculating on what the supply chain crisis would mean for the year’s biggest shopping holiday. By the time shopping began, though, most minds were on another news story. A new Covid-19 variant had been detected in South Africa and it was quickly spreading to Europe. Labeled the omicron variant, this new Covid-19 strain poses a threat to the pandemic recovery story. Perhaps most importantly, we don’t yet know how big that threat is. Scientists haveindicatedthat it will take at least a few weeks for them to assess the effectiveness of vaccines against the new variant, which features multiple mutations. As investors ponder what this means for markets, focus has shifted to one specific question: What does this mean for vaccine stocks?\nInvestors have expressed concern at what the the emergence of a new variant may mean for markets. It bears noting, though, that such a scenario creates a new opportunity for vaccine stocks, specifically for a new company to pull into the lead.\nWhile Pfizer’s(NYSE:PFE) success in producing a vaccine approved for children has helped it maintain a lead over its competitors, other companies recognize the need for further innovation within the vaccine space. Scientists and researchers have yet to reach a conclusion as to how the new variant will react to current vaccines, but the companies producing them are already working around the clock.\nMany vaccine stocks were trending this morning as the omicron variant dominated news coverage. Let’s take a look at what the most prominent vaccine producers are saying and when we can expect to see progress.\n\nModerna(NASDAQ:MRNA)\nPfizer(NYSE:PFE)\nBioNTech (NASDAQ:BNTX)\nJohnson & Johnson(NYSE:JNJ)\nNovavax(NASDAQ:NVAX)\n\nModerna (MRNA)\nModerna was one of the first companies to have its executive team discuss address the omicron variant.\nOn Sunday, CMO Paul Burton spoke toBBC’sAndrew Marr and said Moderna was hoping to see clinical trials of an omicron-specific booster begin within60 to 90 days. CEO Stephane Bancel recentlyspoketoCNBC’s“Squawk Box” on the topic of an omicron- targeting vaccine. While he stated that it will likely take months for the company to develop, produce and ship a vaccine with the ability to target that specific variant, he noted that a booster shot containing a higher 100-microgram dose could be made available much sooner.\nBancel also floated the possibility of administering higher doses of the current vaccines to particularly high-risk patients, such as those in the elderly or immunocompromised categories.\nThis talk of an effective booster that could take on the new variant has sent MRNA stock shooting up today. As of this writing, vaccine stocks are having a good day and Moderna has risen by more than 10%. Today’s gains have put it up by more than 30% for the past five days.\nWhile the head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.\n\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times in an interview.\n\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"\nPfizer (PFE)\nNo pharmaceutical company has received as much positive press for its vaccine innovations as Pfizer. Earlier this month, CEO Albert Bourla wasrecommended by one InvestorPlace contributorfor CEO of the year.\nThe industry leader alsodiscussedthe new variant earlier today, stating that he believed that Pfizer’s Covid-19 pill would prove effective against it. He noted that the treatment method was designed with the thought process that most virus mutations were coming in spikes, exactly what we are seeing so far from the omicron variant. This gives him, he said, a “very high level of confidence” that the oral treatment, Paxlovid, will prove well-suited to help patients with the new Covid-19 strain.\nClinical trials have found that when Paxlovid is taken with HIV drug ritonavir, it reduces hospitalization and death by 89% if taken within three days after symptoms have begun.\nWhile Bourla is still not able to offer much on the effectiveness of the company’s two-dose vaccine against the new variant, he experts it to offer at least some protection. He also said that Pfizer is already at work on a new vaccine and that it produced a DNA template on Friday, speculating that it could be ready within 100 days.\nIt is worth noting that Pfizer has been able to create vaccines for previous variants in that timeframe but did not end up having to administer them, as the previously distributed vaccines remained effective.\nBioNTech (BNTX)\nPfizer’s original vaccine partner isn’t missing a beat, either.\nThe German biotech innovatortoldBusiness Insiderthat it is already at work on the development of an adapted vaccine to combat the omicron variant. According to the company’s spokespeople, the first steps of such a process “overlap with the research necessary” to evaluate the necessity of a new shot. This approach should enable its research team to move forward as quickly as possible.\nLike its competitors, BioNTech expects to acquire the data necessary to determine next steps in roughly two weeks, as medical researchers rush to examine new cases. In an attempt to keep the process as efficient as possible, the company is already testing its existing vaccine doses. Like Pfizer, it claims that it will be able to ship out this adapted vaccine within 100 days should it prove necessary.\nLike other vaccine stocks, BNTX is having a good day as speculation regarding the vaccine mounts. Shares are up almost 4% as of this writing. Not unlike its competitor Moderna, BioNTech is up almost 20% for the week after seeing a period of mostly flatlining. Earlier this Summer,InvestorPlace analyst Louis Navelliercalledit a better buy among vaccine stocks than Pfizer.\nJohnson & Johnson (JNJ)\nLike its competitors, Johnson & Johnson is already at work on ways to combat the new variant. Still waiting on further data, though, the company hasstatedit “will progress [its new vaccine] into clinical studies if needed.”\nMathai Mammen, global head of research and development at J&J subsidiary Janssen Pharmaceuticals, says that the company remains confident in the “robust humoral and cell-mediated responses” that its original vaccine has elicited in patients to date, giving the company confidence in its ability to adapt its current vaccine to handle the omicron variant.\nMammen added that the company has already begun work on a new vaccine for exactly that purpose and will “rapidly progress into clinical trails” if it is deemed necessary. It has beenreportedthat testing has already begun.\nNovavax (NVAX)\nA later player to the vaccine race, Novavax hasn’t had the same success in the U.S. as Pfizer or Moderna.\nHowever, the company recognizes it has a chance to make up the lost ground. In fact, it is already working to develop a vaccine to combat the omicron variant. Novavax hasstatedthat its vaccine will contain the mutated spikes that have experts worried about the variant, thereby enabling recipients to develop necessary immune responses. Its spokespeople have also stated that the testing and developing of the new vaccine will likely take “a few weeks.”\nWhile Novavax has not filed for approval for its initial Covid-19 in the U.S. yet, it received the green light from regulators in both Indonesia and the Philippines.\nAs InvestorPlace Assistant News Writer Eddie Pan reported this morning, NVAX is a name to watch among vaccine stocks as speculation mounts. While no one is likely to know too much for at least two weeks, companies aren’t wasting any time in building on their vaccine innovations in attempt to pull ahead in the vaccine race. Novavax may not have garnered U.S. authorization yet, but it has risen to prominence by way of its global vaccine distribution work, an edge that earned it ahigh rankingamong second-shot vaccine stocks to buy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":769,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878881011,"gmtCreate":1637165457292,"gmtModify":1637165457292,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Up up and away 🎈🎈🎈","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Up up and away 🎈🎈🎈","text":"$AMC Entertainment(AMC)$Up up and away 🎈🎈🎈","images":[{"img":"https://static.tigerbbs.com/1ff4df647da9a225a664bffb876766df","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/878881011","isVote":1,"tweetType":1,"viewCount":215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":609268524,"gmtCreate":1638286630401,"gmtModify":1638286630499,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[开心]&nbsp;","listText":"[开心]&nbsp;","text":"[开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609268524","repostId":"2187817235","repostType":4,"repost":{"id":"2187817235","pubTimestamp":1638279553,"share":"https://www.laohu8.com/m/news/2187817235?lang=&edition=full","pubTime":"2021-11-30 21:39","market":"us","language":"en","title":"4 Stocks Billionaires Are Buying Hand Over Fist","url":"https://stock-news.laohu8.com/highlight/detail?id=2187817235","media":"Motley Fool","summary":"Successful money managers purchased a number of unexpected stocks in the third quarter.","content":"<p>You may not realize it, but one of the most important data releases of the quarter occurred approximately two weeks ago.</p>\n<p>On Nov. 15, institutional investors and hedge funds with at least $100 million in assets under management were required to file Form 13F with the Securities and Exchange Commission (SEC). A 13F provides Wall Street and investors with an under-the-hood look at what the smartest money managers were buying and selling in the previous quarter (i.e., the third quarter). Though 13Fs are a bit dated by the time they're filed with the SEC (holdings are as of Sept. 30, 2021), they still provide valuable clues of what's catching the attention of the world's most successful fund managers.</p>\n<p>With the latest round of 13Fs, one thing stands out: billionaires were buying stocks hand over fist. However, they didn't necessarily buy the names you'd expect.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F654909%2Fbusinessman-looking-at-ticker-board-stock-market-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Ken Griffin (Citadel Advisors): Tesla Motors</h2>\n<p>Billionaire Ken Griffin is a wildly successful investor who's known for extracting big wins from his firms' options positions. But the big story from the third quarter is that Citadel made electric vehicle (EV) manufacturer <b>Tesla Motors</b> (NASDAQ:TSLA) its largest non-options holding. Griffin's fund bought close to 1.8 million shares of Tesla in the third quarter, increasing its position by 873% from the end of June.</p>\n<p>Why Tesla? One logical explanation is that EVs are inevitable. Pretty much every major economic powerhouse worldwide is focused on reducing carbon emissions going forward. Perhaps the easiest way to make a dent in carbon emissions is to push a multi-decade vehicle replacement cycle.</p>\n<p>A more likely explanation for Griffin's interest in Tesla is the company's first-mover advantage. Even with an ongoing semiconductor chip shortage, Tesla looks to be on pace to hit 800,000 (or more) EV deliveries in 2021. Further, it could reasonably pace 50% annual delivery growth over the next couple of years as new gigafactories come online. With no other automakers coming close (at the moment) to its combination of battery range, power, and capacity, Griffin likely feels he and his fund can ride this momentum higher.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F654909%2Fko-drink-bottle.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"><span>Image source: Coca-Cola.</span></p>\n<h2>Jim Simons (Renaissance Technologies): Coca-Cola</h2>\n<p>For a highly diversified fund known for its love of innovation, the shock of the quarter might just be that billionaire Jim Simons was buying beverage giant <b>Coca-Cola</b> (NYSE:KO) hand over fist. All told, Renaissance Technologies added a little over 6 million shares of Coke in the third quarter, which more than tripled its stake as of the end of June.</p>\n<p>With the benchmark <b>S&amp;P 500</b> taking less than 17 months to double from its coronavirus bear-market bottom, Simons' substantially increased stake in Coke might be a means of playing it safe and hedging his funds' bets. Since Coca-Cola has a presence in all but two countries worldwide (Cuba and North Korea), and its portfolio sports more than 20 brands generating at least $1 billion in annual sales, it's a safe bet to generate modest returns -- or at worst hold up much better than the broader market if a crash or correction strikes.</p>\n<p>Coca-Cola is also a relatively smart inflation play. The company is parsing out a hearty 3.1% yield, has raised its base annual dividend for 59 consecutive years, and its well-known brand makes it easy for the company to pass along higher costs to its customers.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F654909%2Fmature-woman-shopping-mall-retail-gdp-clothing-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>David Tepper (Appaloosa): Macy's</h2>\n<p>In a market dominated by growth stocks, billionaire David Tepper headed to the retail counter in the third quarter and piled into department store <b>Macy's</b> (NYSE:M). Tepper's Appaloosa purchased 3.39 million shares, which lifted the fund's stake to an even 7 million shares.</p>\n<p>Scratching your head as to why a successful money manager is buying into an old-school retailer? The answer looks to be Macy's, thus far, solid execution on its three-year Polaris strategy. In no particular order, this strategy includes:</p>\n<ul>\n <li>Closing underperforming stores and reducing corporate and store-level staff to cut expenses.</li>\n <li>Emphasizing digital sales channels, which are a high-growth opportunity for the company until the pandemic ends (and perhaps well after).</li>\n <li>Increasing customer engagement through its loyalty rewards program.</li>\n <li>Focusing its efforts of a small number of higher-margin private brands.</li>\n</ul>\n<p>Although Macy's has challenges to overcome, such as continuing to pay down more than $6 billion in debt, the initial results show its digitization and branding efforts are paying off. The company ended September with 4.4 million new customers, up 28% from the comparable period in 2019 (i.e., before the pandemic). Additionally, 33% of net sales derived online, up from 23% in Q3 2019.&nbsp; If these arrows continue to point higher, Tepper may have found himself a bargain.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F654909%2Fwoman-talk-smartphone-city-wireless-5g-4g-data-voicemail-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Israel Englander (Millennium Management): AT&amp;T</h2>\n<p>Like Ken Griffin, billionaire Israel Englander is a big fan of utilizing put and call options to maximize returns for his fund, Millennium Management. However, the big buy in the third quarter was stodgy telecom giant <b>AT&amp;T</b> (NYSE:T). Englander's fund bought up close to 11.2 million shares, which increased its stake by 165% from the sequential second quarter.</p>\n<p>Similar to Coca-Cola, buying AT&amp;T is a play on value and stability in a very pricey market. For the time being, it's paying out an inflation-topping 8.6% yield and can be purchased for a little north of 7 times Wall Street's estimated earnings per share this year.</p>\n<p>But what might have wet Englander's whistle is AT&amp;T's plan to spin off its content arm, WarnerMedia, and combine it with <b>Discovery</b>. Combining forces will save more than $3 billion in annual costs and vastly improve original and sports programming options for streaming customers. Most importantly, it'll allow AT&amp;T to reduce its debt (and its dividend, as well) and focus on growing its wireless business with the ongoing rollout of 5G infrastructure.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Stocks Billionaires Are Buying Hand Over Fist</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Stocks Billionaires Are Buying Hand Over Fist\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 21:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/30/4-stocks-billionaires-are-buying-hand-over-fist/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may not realize it, but one of the most important data releases of the quarter occurred approximately two weeks ago.\nOn Nov. 15, institutional investors and hedge funds with at least $100 million ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/30/4-stocks-billionaires-are-buying-hand-over-fist/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4515":"5G概念","BK4532":"文艺复兴科技持仓","BK4177":"软饮料","M":"梅西百货","BK4534":"瑞士信贷持仓","BK4507":"流媒体概念","BK4555":"新能源车","EV":"MAST GLOBAL BATTERY RECYCLING & PRODUCTION ETF","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","KO":"可口可乐","BK4115":"综合电信业务","TSLA":"特斯拉","BK4551":"寇图资本持仓","BK4103":"百货商店","BK4504":"桥水持仓","T":"美国电话电报","BK4099":"汽车制造商","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2021/11/30/4-stocks-billionaires-are-buying-hand-over-fist/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2187817235","content_text":"You may not realize it, but one of the most important data releases of the quarter occurred approximately two weeks ago.\nOn Nov. 15, institutional investors and hedge funds with at least $100 million in assets under management were required to file Form 13F with the Securities and Exchange Commission (SEC). A 13F provides Wall Street and investors with an under-the-hood look at what the smartest money managers were buying and selling in the previous quarter (i.e., the third quarter). Though 13Fs are a bit dated by the time they're filed with the SEC (holdings are as of Sept. 30, 2021), they still provide valuable clues of what's catching the attention of the world's most successful fund managers.\nWith the latest round of 13Fs, one thing stands out: billionaires were buying stocks hand over fist. However, they didn't necessarily buy the names you'd expect.\nImage source: Getty Images.\nKen Griffin (Citadel Advisors): Tesla Motors\nBillionaire Ken Griffin is a wildly successful investor who's known for extracting big wins from his firms' options positions. But the big story from the third quarter is that Citadel made electric vehicle (EV) manufacturer Tesla Motors (NASDAQ:TSLA) its largest non-options holding. Griffin's fund bought close to 1.8 million shares of Tesla in the third quarter, increasing its position by 873% from the end of June.\nWhy Tesla? One logical explanation is that EVs are inevitable. Pretty much every major economic powerhouse worldwide is focused on reducing carbon emissions going forward. Perhaps the easiest way to make a dent in carbon emissions is to push a multi-decade vehicle replacement cycle.\nA more likely explanation for Griffin's interest in Tesla is the company's first-mover advantage. Even with an ongoing semiconductor chip shortage, Tesla looks to be on pace to hit 800,000 (or more) EV deliveries in 2021. Further, it could reasonably pace 50% annual delivery growth over the next couple of years as new gigafactories come online. With no other automakers coming close (at the moment) to its combination of battery range, power, and capacity, Griffin likely feels he and his fund can ride this momentum higher.\nImage source: Coca-Cola.\nJim Simons (Renaissance Technologies): Coca-Cola\nFor a highly diversified fund known for its love of innovation, the shock of the quarter might just be that billionaire Jim Simons was buying beverage giant Coca-Cola (NYSE:KO) hand over fist. All told, Renaissance Technologies added a little over 6 million shares of Coke in the third quarter, which more than tripled its stake as of the end of June.\nWith the benchmark S&P 500 taking less than 17 months to double from its coronavirus bear-market bottom, Simons' substantially increased stake in Coke might be a means of playing it safe and hedging his funds' bets. Since Coca-Cola has a presence in all but two countries worldwide (Cuba and North Korea), and its portfolio sports more than 20 brands generating at least $1 billion in annual sales, it's a safe bet to generate modest returns -- or at worst hold up much better than the broader market if a crash or correction strikes.\nCoca-Cola is also a relatively smart inflation play. The company is parsing out a hearty 3.1% yield, has raised its base annual dividend for 59 consecutive years, and its well-known brand makes it easy for the company to pass along higher costs to its customers.\nImage source: Getty Images.\nDavid Tepper (Appaloosa): Macy's\nIn a market dominated by growth stocks, billionaire David Tepper headed to the retail counter in the third quarter and piled into department store Macy's (NYSE:M). Tepper's Appaloosa purchased 3.39 million shares, which lifted the fund's stake to an even 7 million shares.\nScratching your head as to why a successful money manager is buying into an old-school retailer? The answer looks to be Macy's, thus far, solid execution on its three-year Polaris strategy. In no particular order, this strategy includes:\n\nClosing underperforming stores and reducing corporate and store-level staff to cut expenses.\nEmphasizing digital sales channels, which are a high-growth opportunity for the company until the pandemic ends (and perhaps well after).\nIncreasing customer engagement through its loyalty rewards program.\nFocusing its efforts of a small number of higher-margin private brands.\n\nAlthough Macy's has challenges to overcome, such as continuing to pay down more than $6 billion in debt, the initial results show its digitization and branding efforts are paying off. The company ended September with 4.4 million new customers, up 28% from the comparable period in 2019 (i.e., before the pandemic). Additionally, 33% of net sales derived online, up from 23% in Q3 2019.  If these arrows continue to point higher, Tepper may have found himself a bargain.\nImage source: Getty Images.\nIsrael Englander (Millennium Management): AT&T\nLike Ken Griffin, billionaire Israel Englander is a big fan of utilizing put and call options to maximize returns for his fund, Millennium Management. However, the big buy in the third quarter was stodgy telecom giant AT&T (NYSE:T). Englander's fund bought up close to 11.2 million shares, which increased its stake by 165% from the sequential second quarter.\nSimilar to Coca-Cola, buying AT&T is a play on value and stability in a very pricey market. For the time being, it's paying out an inflation-topping 8.6% yield and can be purchased for a little north of 7 times Wall Street's estimated earnings per share this year.\nBut what might have wet Englander's whistle is AT&T's plan to spin off its content arm, WarnerMedia, and combine it with Discovery. Combining forces will save more than $3 billion in annual costs and vastly improve original and sports programming options for streaming customers. Most importantly, it'll allow AT&T to reduce its debt (and its dividend, as well) and focus on growing its wireless business with the ongoing rollout of 5G infrastructure.","news_type":1},"isVote":1,"tweetType":1,"viewCount":713,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609263541,"gmtCreate":1638286522611,"gmtModify":1638286522611,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"That's great","listText":"That's great","text":"That's great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609263541","repostId":"2187580541","repostType":4,"repost":{"id":"2187580541","pubTimestamp":1638286205,"share":"https://www.laohu8.com/m/news/2187580541?lang=&edition=full","pubTime":"2021-11-30 23:30","market":"us","language":"en","title":"These 3 Charts Should Have Nio Investors Excited","url":"https://stock-news.laohu8.com/highlight/detail?id=2187580541","media":"Motley Fool","summary":"While Tesla is expanding in Nio's domestic market, the Chinese electric vehicle maker is moving into another major market, too.","content":"<p>The field of stocks in the electric vehicle (EV) sector has been growing rapidly. Investors can now choose from among a host of legacy automakers working to transition from internal combustion, start-ups with much promise, and established EV manufacturers that continue to grow.</p>\n<p>Chinese EV maker <b>Nio</b> (NYSE:NIO) is in that third group, but its stock has been out of favor on Wall Street in 2021 -- the stock price is down about 17% year to date. However, if you take a closer look at some data related to the company and its market, you'll see that Nio has the potential to deliver much better results from here.</p>\n<p>Here are three charts that should have Nio investors excited.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F654894%2Fnioet7technology.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Nio ET7 electric sedan in aerodynamic testing. Image source: Nio.</span></p>\n<h2>1. Nio has more room to run</h2>\n<p>This year's lackluster returns from Nio should be put in perspective. Its stock handily outperformed <b>Tesla </b>(NASDAQ:TSLA) in 2020.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/73933108431bcd85aefb1afdea7e690d\" tg-width=\"720\" tg-height=\"387\" width=\"100%\" height=\"auto\"><span>NIO data by YCharts</span></p>\n<p>But calendar years are an arbitrary and incomplete way to gauge returns, and Tesla, of course, has been the king of EV stocks over the longer term. While Nio has slipped during 2021, Tesla's share price has continued to rise, pushing the EV leader's market cap above $1 trillion. Nio, meanwhile, is valued at slightly over $60 billion.</p>\n<h2>2. Measuring the market shows plenty of growth ahead</h2>\n<p>Tesla built its first non-U.S. manufacturing plant in China for a reason. China is the largest global automotive market. But Europe overtook it as the largest market for EVs in 2020, as measured by new registrations, according to the International Energy Agency (IEA). And while Tesla is growing its footprint in China, Nio is pushing into the European market. It launched sales in Norway in September, and next year will begin doing business in Germany.</p>\n<p>Sales of electric passenger cars have soared in recent years, and the IEA predicts that growth will remain dramatic over the next decade. The data below is for battery electric vehicles and does not even include plug-in hybrid vehicles, which some consumers may pick as stepping stones in their transitions to fully electric vehicles.</p>\n<table border=\"1\">\n <tbody>\n  <tr>\n   <th>Metric</th>\n   <th>2015</th>\n   <th>2020</th>\n   <th>2025 (Forecast)</th>\n   <th>2030 (Forecast)</th>\n  </tr>\n  <tr>\n   <td>Passenger EV Sales (Global)</td>\n   <td>700,000</td>\n   <td>6.8 million</td>\n   <td>29.6 million</td>\n   <td>80 million</td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: IEA 2021 Global EV Outlook</p>\n<p>The IEA's estimates represent its stated policy scenario for passenger cars. It also sees the possibility of more than 138 million passenger battery electric vehicles sold cumulatively by 2030 if governments adopt sustainable development policies.</p>\n<h2>3. Nio is getting a bigger piece of a pie that's also growing</h2>\n<p>Nio and its manufacturing partner have an expansion project underway. Once they complete it this spring, the company will have the rated capacity to produce 250,000 EVs annually, and management has said that with overtime and other actions, it could push production to 300,000. That sets the company up to continue growing much as it has over the past two years.</p>\n<table border=\"1\">\n <tbody>\n  <tr>\n   <th></th>\n   <th>Q3 2019</th>\n   <th>Q3 2020</th>\n   <th>Q3 2021</th>\n  </tr>\n  <tr>\n   <td>Nio vehicle deliveries</td>\n   <td>4,799</td>\n   <td>12,206</td>\n   <td>24,439</td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: Nio financial releases.</p>\n<p>Over the past two years, Nio's Q3 sales have risen at an annualized rate of more than 125%. But its current levels are still a drop in the bucket compared to what market demand would sustain.</p>\n<p>There's plenty of competition in the EV sector. But Nio has added manufacturing capacity and is focusing on the two markets that are responsible for the most electric vehicle sales right now. Over time, investors could see plenty of appreciation in the stock if Nio executes well on its plans to grow sales in China, Europe, and beyond.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 3 Charts Should Have Nio Investors Excited</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 3 Charts Should Have Nio Investors Excited\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/30/these-3-charts-should-have-nio-investors-excited/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The field of stocks in the electric vehicle (EV) sector has been growing rapidly. Investors can now choose from among a host of legacy automakers working to transition from internal combustion, start-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/30/these-3-charts-should-have-nio-investors-excited/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","BK4211":"区域性银行"},"source_url":"https://www.fool.com/investing/2021/11/30/these-3-charts-should-have-nio-investors-excited/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2187580541","content_text":"The field of stocks in the electric vehicle (EV) sector has been growing rapidly. Investors can now choose from among a host of legacy automakers working to transition from internal combustion, start-ups with much promise, and established EV manufacturers that continue to grow.\nChinese EV maker Nio (NYSE:NIO) is in that third group, but its stock has been out of favor on Wall Street in 2021 -- the stock price is down about 17% year to date. However, if you take a closer look at some data related to the company and its market, you'll see that Nio has the potential to deliver much better results from here.\nHere are three charts that should have Nio investors excited.\nNio ET7 electric sedan in aerodynamic testing. Image source: Nio.\n1. Nio has more room to run\nThis year's lackluster returns from Nio should be put in perspective. Its stock handily outperformed Tesla (NASDAQ:TSLA) in 2020.\nNIO data by YCharts\nBut calendar years are an arbitrary and incomplete way to gauge returns, and Tesla, of course, has been the king of EV stocks over the longer term. While Nio has slipped during 2021, Tesla's share price has continued to rise, pushing the EV leader's market cap above $1 trillion. Nio, meanwhile, is valued at slightly over $60 billion.\n2. Measuring the market shows plenty of growth ahead\nTesla built its first non-U.S. manufacturing plant in China for a reason. China is the largest global automotive market. But Europe overtook it as the largest market for EVs in 2020, as measured by new registrations, according to the International Energy Agency (IEA). And while Tesla is growing its footprint in China, Nio is pushing into the European market. It launched sales in Norway in September, and next year will begin doing business in Germany.\nSales of electric passenger cars have soared in recent years, and the IEA predicts that growth will remain dramatic over the next decade. The data below is for battery electric vehicles and does not even include plug-in hybrid vehicles, which some consumers may pick as stepping stones in their transitions to fully electric vehicles.\n\n\n\nMetric\n2015\n2020\n2025 (Forecast)\n2030 (Forecast)\n\n\nPassenger EV Sales (Global)\n700,000\n6.8 million\n29.6 million\n80 million\n\n\n\nData source: IEA 2021 Global EV Outlook\nThe IEA's estimates represent its stated policy scenario for passenger cars. It also sees the possibility of more than 138 million passenger battery electric vehicles sold cumulatively by 2030 if governments adopt sustainable development policies.\n3. Nio is getting a bigger piece of a pie that's also growing\nNio and its manufacturing partner have an expansion project underway. Once they complete it this spring, the company will have the rated capacity to produce 250,000 EVs annually, and management has said that with overtime and other actions, it could push production to 300,000. That sets the company up to continue growing much as it has over the past two years.\n\n\n\n\nQ3 2019\nQ3 2020\nQ3 2021\n\n\nNio vehicle deliveries\n4,799\n12,206\n24,439\n\n\n\nData source: Nio financial releases.\nOver the past two years, Nio's Q3 sales have risen at an annualized rate of more than 125%. But its current levels are still a drop in the bucket compared to what market demand would sustain.\nThere's plenty of competition in the EV sector. But Nio has added manufacturing capacity and is focusing on the two markets that are responsible for the most electric vehicle sales right now. Over time, investors could see plenty of appreciation in the stock if Nio executes well on its plans to grow sales in China, Europe, and beyond.","news_type":1},"isVote":1,"tweetType":1,"viewCount":415,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872060771,"gmtCreate":1637376084068,"gmtModify":1637376084211,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>BBelieve in it","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>BBelieve in it","text":"$NIO Inc.(NIO)$BBelieve in it","images":[{"img":"https://static.tigerbbs.com/32398208a6a07772e95d13e64149542c","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/872060771","isVote":1,"tweetType":1,"viewCount":511,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":878686271,"gmtCreate":1637190219247,"gmtModify":1637190219247,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SEV\">$Sono Group N.V.(SEV)$</a>ttought that wouldn't make it&nbsp;[得意]&nbsp;","listText":"<a href=\"https://laohu8.com/S/SEV\">$Sono Group N.V.(SEV)$</a>ttought that wouldn't make it&nbsp;[得意]&nbsp;","text":"$Sono Group N.V.(SEV)$ttought that wouldn't make it [得意]","images":[{"img":"https://static.tigerbbs.com/ad5b5c16d3d74044165374a4b39b85da","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878686271","isVote":1,"tweetType":1,"viewCount":115,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":609263789,"gmtCreate":1638286545384,"gmtModify":1638286545384,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609263789","repostId":"1181644709","repostType":4,"repost":{"id":"1181644709","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638284868,"share":"https://www.laohu8.com/m/news/1181644709?lang=&edition=full","pubTime":"2021-11-30 23:07","market":"us","language":"en","title":"Gaming stocks jumped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1181644709","media":"Tiger Newspress","summary":"Gaming stocks jumped in morning trading.Roblox,Unity Software and Electronic Arts climbed between 2%","content":"<p>Gaming stocks jumped in morning trading.Roblox,Unity Software and Electronic Arts climbed between 2% and 5%.</p>\n<p><img src=\"https://static.tigerbbs.com/9aff3bf3e56d9e3cf17dfc21e823a602\" tg-width=\"399\" tg-height=\"365\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gaming stocks jumped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGaming stocks jumped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-30 23:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gaming stocks jumped in morning trading.Roblox,Unity Software and Electronic Arts climbed between 2% and 5%.</p>\n<p><img src=\"https://static.tigerbbs.com/9aff3bf3e56d9e3cf17dfc21e823a602\" tg-width=\"399\" tg-height=\"365\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","EA":"艺电","RBLX":"Roblox Corporation"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181644709","content_text":"Gaming stocks jumped in morning trading.Roblox,Unity Software and Electronic Arts climbed between 2% and 5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":388,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600545182,"gmtCreate":1638179310187,"gmtModify":1638180396728,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oo","listText":"Oo","text":"Oo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600545182","repostId":"1193304775","repostType":4,"repost":{"id":"1193304775","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1638178459,"share":"https://www.laohu8.com/m/news/1193304775?lang=&edition=full","pubTime":"2021-11-29 17:34","market":"us","language":"en","title":"5 Stocks To Watch For November 29, 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1193304775","media":"Benzinga","summary":"Some of the stocks that may grab investor focus today are:\n\nLi Auto's Q3 results beat estimates.its ","content":"<p>Some of the stocks that may grab investor focus today are:</p>\n<ul>\n <li>Li Auto's Q3 results beat estimates.its&nbsp;total revenues reached $1.21 billion;deliveries reached 25,116 vehicles;gross margin reached 23.3%.Wall Street expects&nbsp;<b>Li Auto Inc.</b>&nbsp;to report a quarterly loss at $0.02 per share on revenue of $1.16 billion before the opening bell. Li Auto shares rose 5.8% to $34.29 in premarket trading&nbsp;Monday.</li>\n <li><b>Moderna, Inc.</b>, which was the second biopharma company to get authorization for a COVID-19 vaccine, is confident it will have something on the table shortly to tackle the latest virus threat. The company’s current vaccine will be tested against the new variant, and its ability to offer immunity will likely be known over the next couple of weeks, the company's chief medical officer Paul Burton reportedly said on BBC's \"Andrew Marr Show.\" Moderna shares rose 10.2% to $363.3 in premarket tradingMonday.</li>\n <li>Analysts are expecting&nbsp;<b>StoneX Group Inc.</b>&nbsp;to have earned $1.44 per share on revenue of $280.55 million for the latest quarter. The company will release earnings after the closing bell. StoneX shares dropped 3.4% to close at $66.70 on Friday.</li>\n</ul>\n<ul>\n <li><b>Tesla, Inc</b>&nbsp;will likely commence production operations at its Giga Berlin in Germany in December, Bloomberg reported, citing German magazine Automobilwoche. Tesla shares rallied more&nbsp;than&nbsp;2% to $1,106.2 in premarket tradingMonday.</li>\n <li>Frontline's Q3 results missed estimates.Analysts expect&nbsp;<b>Frontline Ltd.</b>&nbsp;to post a quarterly loss at $1.58 per share on revenue of $605.57 million before the opening bell. Frontline shares dropped 2.8% to&nbsp;$6.61 in premarket tradingMonday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For November 29, 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For November 29, 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-11-29 17:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Some of the stocks that may grab investor focus today are:</p>\n<ul>\n <li>Li Auto's Q3 results beat estimates.its&nbsp;total revenues reached $1.21 billion;deliveries reached 25,116 vehicles;gross margin reached 23.3%.Wall Street expects&nbsp;<b>Li Auto Inc.</b>&nbsp;to report a quarterly loss at $0.02 per share on revenue of $1.16 billion before the opening bell. Li Auto shares rose 5.8% to $34.29 in premarket trading&nbsp;Monday.</li>\n <li><b>Moderna, Inc.</b>, which was the second biopharma company to get authorization for a COVID-19 vaccine, is confident it will have something on the table shortly to tackle the latest virus threat. The company’s current vaccine will be tested against the new variant, and its ability to offer immunity will likely be known over the next couple of weeks, the company's chief medical officer Paul Burton reportedly said on BBC's \"Andrew Marr Show.\" Moderna shares rose 10.2% to $363.3 in premarket tradingMonday.</li>\n <li>Analysts are expecting&nbsp;<b>StoneX Group Inc.</b>&nbsp;to have earned $1.44 per share on revenue of $280.55 million for the latest quarter. The company will release earnings after the closing bell. StoneX shares dropped 3.4% to close at $66.70 on Friday.</li>\n</ul>\n<ul>\n <li><b>Tesla, Inc</b>&nbsp;will likely commence production operations at its Giga Berlin in Germany in December, Bloomberg reported, citing German magazine Automobilwoche. Tesla shares rallied more&nbsp;than&nbsp;2% to $1,106.2 in premarket tradingMonday.</li>\n <li>Frontline's Q3 results missed estimates.Analysts expect&nbsp;<b>Frontline Ltd.</b>&nbsp;to post a quarterly loss at $1.58 per share on revenue of $605.57 million before the opening bell. Frontline shares dropped 2.8% to&nbsp;$6.61 in premarket tradingMonday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","LI":"理想汽车","TSLA":"特斯拉","SNEX":"StoneX Group Inc.","FRO":"FRONTLINE PLC"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193304775","content_text":"Some of the stocks that may grab investor focus today are:\n\nLi Auto's Q3 results beat estimates.its total revenues reached $1.21 billion;deliveries reached 25,116 vehicles;gross margin reached 23.3%.Wall Street expects Li Auto Inc. to report a quarterly loss at $0.02 per share on revenue of $1.16 billion before the opening bell. Li Auto shares rose 5.8% to $34.29 in premarket trading Monday.\nModerna, Inc., which was the second biopharma company to get authorization for a COVID-19 vaccine, is confident it will have something on the table shortly to tackle the latest virus threat. The company’s current vaccine will be tested against the new variant, and its ability to offer immunity will likely be known over the next couple of weeks, the company's chief medical officer Paul Burton reportedly said on BBC's \"Andrew Marr Show.\" Moderna shares rose 10.2% to $363.3 in premarket tradingMonday.\nAnalysts are expecting StoneX Group Inc. to have earned $1.44 per share on revenue of $280.55 million for the latest quarter. The company will release earnings after the closing bell. StoneX shares dropped 3.4% to close at $66.70 on Friday.\n\n\nTesla, Inc will likely commence production operations at its Giga Berlin in Germany in December, Bloomberg reported, citing German magazine Automobilwoche. Tesla shares rallied more than 2% to $1,106.2 in premarket tradingMonday.\nFrontline's Q3 results missed estimates.Analysts expect Frontline Ltd. to post a quarterly loss at $1.58 per share on revenue of $605.57 million before the opening bell. Frontline shares dropped 2.8% to $6.61 in premarket tradingMonday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":298,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874831562,"gmtCreate":1637754053562,"gmtModify":1637754058082,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oo","listText":"Oo","text":"Oo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874831562","repostId":"1199806578","repostType":2,"repost":{"id":"1199806578","pubTimestamp":1637744080,"share":"https://www.laohu8.com/m/news/1199806578?lang=&edition=full","pubTime":"2021-11-24 16:54","market":"us","language":"en","title":"5 Stocks To Watch For November 24, 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1199806578","media":"Benzinga","summary":"Some of the stocks that may grab investor focus today are:\n\nWall Street expects Deere & Company to r","content":"<p>Some of the stocks that may grab investor focus today are:</p>\n<ul>\n <li>Wall Street expects&nbsp;<b>Deere &amp; Company</b>&nbsp;to report quarterly earnings at $3.90 per share on revenue of $10.44 billion before the opening bell. Deere shares fell 0.7% to $347.01 in after-hours trading.</li>\n <li><b>HP Inc</b>&nbsp;reported better-than-expected results for its fourth quarter and issued strong earnings forecast for the current quarter. HP shares surged climbed 7.5% to $34.60 in the after-hours trading session.</li>\n <li><b>Autodesk, Inc.</b>&nbsp;reported upbeat results for its third quarter, but issued disappointing guidance. Autodesk said it sees Q4 revenue of $1.185 billion to $1.2 billion and non-GAAP earnings of $1.41 to $1.47 per share. Autodesk shares dipped 14.5% to $259.99 in the after-hours trading session.</li>\n</ul>\n<ul>\n <li><b>Dell Technologies Inc.</b>&nbsp;posted stronger-than-expected earnings and sales results for its third quarter on Tuesday. Dell shares gained 1.5% to $55.50 in the after-hours trading session.</li>\n <li><b>The Gap, Inc.</b>&nbsp;reported weaker-than-expected results for its third quarter and lowered its FY21 earnings guidance. Gap shares dipped 16.3% to $19.69 in the after-hours trading session.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For November 24, 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For November 24, 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 16:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/earnings/21/11/24269055/5-stocks-to-watch-for-november-24-2021><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Some of the stocks that may grab investor focus today are:\n\nWall Street expects Deere & Company to report quarterly earnings at $3.90 per share on revenue of $10.44 billion before the opening bell. ...</p>\n\n<a href=\"https://www.benzinga.com/news/earnings/21/11/24269055/5-stocks-to-watch-for-november-24-2021\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DE":"迪尔股份有限公司","GPS":"盖璞","DELL":"戴尔","ADSK":"欧特克","HPQ":"惠普"},"source_url":"https://www.benzinga.com/news/earnings/21/11/24269055/5-stocks-to-watch-for-november-24-2021","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199806578","content_text":"Some of the stocks that may grab investor focus today are:\n\nWall Street expects Deere & Company to report quarterly earnings at $3.90 per share on revenue of $10.44 billion before the opening bell. Deere shares fell 0.7% to $347.01 in after-hours trading.\nHP Inc reported better-than-expected results for its fourth quarter and issued strong earnings forecast for the current quarter. HP shares surged climbed 7.5% to $34.60 in the after-hours trading session.\nAutodesk, Inc. reported upbeat results for its third quarter, but issued disappointing guidance. Autodesk said it sees Q4 revenue of $1.185 billion to $1.2 billion and non-GAAP earnings of $1.41 to $1.47 per share. Autodesk shares dipped 14.5% to $259.99 in the after-hours trading session.\n\n\nDell Technologies Inc. posted stronger-than-expected earnings and sales results for its third quarter on Tuesday. Dell shares gained 1.5% to $55.50 in the after-hours trading session.\nThe Gap, Inc. reported weaker-than-expected results for its third quarter and lowered its FY21 earnings guidance. Gap shares dipped 16.3% to $19.69 in the after-hours trading session.","news_type":1},"isVote":1,"tweetType":1,"viewCount":416,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872060131,"gmtCreate":1637376029766,"gmtModify":1637376029924,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Not earning much as compared to prev record but all good","listText":"Not earning much as compared to prev record but all good","text":"Not earning much as compared to prev record but all good","images":[{"img":"https://static.tigerbbs.com/97c01b15c123070a68e19134ae90eee1","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872060131","isVote":1,"tweetType":1,"viewCount":577,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":876947797,"gmtCreate":1637253265603,"gmtModify":1637253266704,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SEV\">$Sono Group N.V.(SEV)$</a>😅","listText":"<a href=\"https://laohu8.com/S/SEV\">$Sono Group N.V.(SEV)$</a>😅","text":"$Sono Group N.V.(SEV)$😅","images":[{"img":"https://static.tigerbbs.com/150f48431a71c41857a882bc49b29bf5","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876947797","isVote":1,"tweetType":1,"viewCount":376,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":876903747,"gmtCreate":1637247444421,"gmtModify":1637247444421,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"This is nice ☺️","listText":"This is nice ☺️","text":"This is nice ☺️","images":[{"img":"https://static.tigerbbs.com/3fdfd57e4cd4967c6a122cff43245640","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876903747","isVote":1,"tweetType":1,"viewCount":574,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":878800652,"gmtCreate":1637162463472,"gmtModify":1637162463521,"author":{"id":"4099890130933260","authorId":"4099890130933260","name":"Serephine","avatar":"https://static.tigerbbs.com/5c6f074ba0bf28184f32cf1d561d6ed4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[财迷]&nbsp;","listText":"[财迷]&nbsp;","text":"[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878800652","repostId":"1199355122","repostType":2,"isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}